Objective It has been reported that the progestin medroxyprogesterone acetate (MPA), but not norethindrone acetate (NETA), inhibits the beneficial vascular effects of post-menopausal estrogen therapy, but their effects on the myocardium are unclear. The goal of this study is to compare the effects of these two progestins on post-ischemic myocardial damage.
A comparison of two progestins on myocardial ischemia-reperfusion injury in ovariectomized monkeys receiving estrogen therapy Irma H. Suparto a , J. Koudy Williams b , Jamie L. Fox b and Jakob Vinten-Johansen c Objective It has been reported that the progestin medroxyprogesterone acetate (MPA), but not norethindrone acetate (NETA), inhibits the beneficial vascular effects of post-menopausal estrogen therapy, but their effects on the myocardium are unclear. The goal of this study is to compare the effects of these two progestins on post-ischemic myocardial damage.
Methods Ovariectomized monkeys were fed an atherogenic diet for 18 months while receiving, or not receiving (control, n = 15), the monkey equivalent to a woman's dose of 5 lg ethinyl estradiol with either 1 mg NETA daily (n = 15) or 2.5 mg MPA daily (n = 15). The left anterior descending coronary artery was occluded for 1 h and then released to allow myocardial reperfusion for 4 h. Infarct size was quantified using the histochemical stain triphenyl-tetrazolium chloride. Regional myocardial blood flow was measured by 15 lm neutron-activated microspheres, blood pressure and heart rates with a pneumatic cuff, stroke volume by echocardiography, coronary output by thermodilution and neutrophil accumulation in the myocardium using myeloperoxidase (MPO) activity.
Results
The infarct size (area of necrosis/area at risk) was similar between the control group (21 ± 3%) and the MPA group (29 ± 3%) (P < 0.05) but significantly less in the NETA group (3 ± 2%) than other groups (P < 0.05). The hemodynamic myocardial function and regional myocardial blood values were similar among groups before, during and 4 h after reperfusion (all P-values > 0.05). Similarly, there were no treatment effects on MPO activity (P > 0.05).
Conclusions NETA, but not MPA, diminished ischemia-reperfusion injury in estrogen-treated postmenopausal females. The mechanism(s) of this difference remains unclear. Coron Artery Dis 16:301-308 c 2005 Lippincott Williams & Wilkins.
Introduction
The potential health benefit-risk profile of hormone therapy is currently of great concern to post-menopausal women, their physicians and the scientific community as a whole. This concern is based largely on the reported null effects of the hormone replacement therapy containing conjugated equine estrogens (CEE) and medroxyprogesterone acetate (MPA) on primary [1] or secondary [2] prevention of coronary events. However, one aspect of coronary heart disease not addressed by these studies is the amount of myocardial damage that occurs should a woman have a coronary event. A second aspect not addressed was the effect of different estrogen plus progestin regimens on cardiovascular risk. It has been reported that progestins have differential effects on atherogenesis and vascular reactivity when co-administered with estrogens [3] [4] [5] [6] . However, the effects of different progestin therapy on post-ischemic myocardial injury (a measure of post-infarction myocardial damage) in women receiving estrogen replacement are not known.
Following an acute myocardial infarction, re-establishing coronary blood flow with timely reperfusion strategies such as thrombolysis or primary angioplasty is essential to salvage viable myocardium. However, reperfusion of ischemic myocardium carries with it inherent risk, in that the process of reperfusion can itself result in further myocyte damage, a phenomenon termed ischemiareperfusion (I/R) injury [7] [8] [9] It is thought that the rapid influx of oxygenated blood produces a profound inflammatory response in the myocardium, resulting from intensified neutrophil-endothelial cell interactions within the previously ischemic myocardium [7] [8] [9] . Inflammation further damages the myocardium by both stimulating the production of reactive oxygen species (superoxide radicals) and reducing the production of certain cardioprotective factors, such as nitric oxide [7] [8] [9] Reduction of neutrophil-endothelial cell interactions has been reported to be associated with concomitantly reduced infarct size, suggesting a cause-and-effect relationship [10] [11] [12] .
Estrogen significantly reduces myocyte injury, infarct size and incidence of arrhythmias following I/R injury [13] [14] [15] . Furthermore, the cardioprotective effects of estrogen against I/R injury appear to involve attenuated myocardial tissue neutrophil adherence and infiltration [16] and reduced plasma concentrations of myeloperoxidase (MPO) [17] . The rationale for the present study was based on the results of a previously published report from our group indicating that the hormone therapy containing CEE and MPA produced a less beneficial cardiovascular effect (including more heart rate-induced myocardial ischemia) than the hormone therapy containing ethinyl estradiol (EE) and norethindrone acetate (NETA) [6] . Assuming both estrogen therapies were effective in reducing heart rate-induced ischemia (untested here), we hypothesized that the two different progestins (MPA and NETA) may have differential effects on the postischemic myocardium. Therefore, the goal of this study was to compare the effects of two progestins on myocardial infarct size following I/R in ovariectomized monkeys receiving identical estrogen treatments.
Methods

Experimental design
Forty-five adult (10-12 years of age) female cynomolgus monkeys (Macaca fascicularis) were obtained from the Primate Research Center of Bogor Agricultural University, Indonesia. All research was conducted in accordance with practices set forth by The Centers for Disease Control and Prevention and the Wake Forest University Animal Care and Use Committee. Monkeys were fed a moderately atherogenic diet for 3 months prior to the initiation of treatment. The diet contained 19.4% of calories from protein, 42.4% of calories from fat, 38.2% of calories from carbohydrate and 0.28 mg cholesterol per calorie. All animals were housed in social groups of three to four animals per pen throughout the experiment. The experimental design of this experiment is outlined in Figure 1 .
Following quarantine, the monkeys were ovariectomized and then randomized into three experimental groups using a stratified randomization scheme to equalize groups for the ratio of total plasma cholesterol (TPC) to high-density lipoprotein cholesterol (HDL-C), a risk factor for coronary heart disease. The control group received no additions to their atherogenic diet. The second experimental group received EE and MPA added to their atherogenic diet, calorically adjusted to be equivalent to a woman's dose of 5 mg/day EE and 2.5 mg/day MPA, which is the progestin used in the Women's Health Initiative trial. The third experimental group received EE and NETA, which is the progestin used in the hormone therapy Femhrt (Warner Chilcott, Rockaway, New Jersey, USA) and the progestin used in many oral contraceptives, at a dose equivalent to a dose for women of 5 mg/day EE and 1 mg/day NETA (the equivalent to Femhrt). Drug doses were calculated based on the assumption that an average woman consumes approximately 1800 calories per day. Monkeys were fed 120 calories of diet per kilogram of body weight and therefore consumed 0.339 mg/kg body weight of EE and 0.169 mg/kg body weight of MPA or 0.339 mg/kg body weight of EE and 0.068 mg/kg body weight of NETA (groups 2 and 3, respectively). Thirty-nine animals completed this experiment (control, n = 15; EE and MPA, n = 12; EE and NETA, n = 12). Six monkeys died for reasons not related to this study (trauma, intestinal disease).
Measurement of body weight and plasma lipids and lipoproteins
Body weight measurements and plasma lipid determinations were performed at baseline, 6 months after initiation of estrogen and progestin therapy and before necropsy (12 months). After an overnight fast, blood samples for lipoproteins were collected from the femoral vein of tranquilized monkeys into evacuated tubes containing EDTA for determination of TPC concentrations, HDL-C concentrations and triglyceride concentrations [18] [19] [20] . Low-density lipoprotein cholesterol (LDL-C) plus verylow-density lipoprotein cholesterol was calculated as the difference between TPC and HDL-C. 
Surgical preparation for coronary artery occlusionreperfusion protocol
At the end of the treatment period, monkeys were sedated with ketamine and butorphanol (intramuscularly) and then given a-chloralose (100 mg/kg, intravenously) to achieve surgical anesthesia. Monkeys were positive pressure-ventilated at 16 breaths/min with room air supplemented with humidified 95% O 2 /5% CO 2 . A Vetspecs 9062 V-D Vital Signs Monitor (Vetspecs, Canton, Georgia, USA) was used to continuously monitor electrocardiogram recordings, blood oxygen saturation, blood pressure, heart rate and body temperature. A venous catheter was placed in the popliteal vein for administration of intravenous fluids. A Swan-Ganz thermodilution pulmonary arterial catheter (5 F in size, 75 cm in length) (Baxter, Santa Ana, California, USA) was advanced from a femoral vein to the pulmonary artery with the aid of fluoroscopy to measure cardiac output as described previously [21] . A 3 F catheter was advanced from the right femoral artery to the left ventricle using fluoroscopy to inject 15 mm neutron-activated microspheres. Regional myocardial blood flow (ml/min per g tissue) in the area at risk (AAR) and non-ischemic left ventricular free wall was determined at baseline, at ischemia and at 15 min and 3 h of reperfusion using the reference sampling method as previously described [22] . The endpoints and their frequency of measure are found in Table 1 .
Baseline measures of left ventricular ejection fraction (left ventricular diameter during systole -left ventricular diameter during diastole) were obtained using an Aloka 118 echocardiography machine (Colormetrics Medical Systems, Ramsey, New Jersey, USA) using a 5 MHz probe in the M-mode setting.
A left-sided thoracotomy was then performed through the fourth intercostal space and the pericardium was incised widely to visualize the heart. Baseline measures were then taken and the left anterior descending coronary artery occluded immediately distal to its first diagonal branch using a 3-0 silk suture. Occlusion was maintained for 1 h, measurements were repeated and the occlusion released. Measures were taken once every hour for the next 4 h (Table 1) . At the end of 4 h of reperfusion the coronary ligature was re-applied and a 1% solution of Evan's blue dye was injected into the venous system. The monkey was then euthanized using an intravenous bolus of saturated potassium chloride. The heart was rapidly removed.
The heart was sectioned transversely at 3 mm intervals and sections placed in a 1% solution of Triphenyltetrazolium Chloride. After 30 min, the tissue slices were examined and divided into necrotic (stains a tan color) and non-necrotic (red staining) sections. All sections were weighed. AAR and area of necrosis (An) were determined gravimetrically. The AAR as a percentage was calculated as (weight of non-blue tissue/weight of total left ventricle) Â 100. The An was determined as (weight of TTC-negative tissue/weight of AAR) Â 100. Infarct size was calculated as (An/AAR) Â 100 and presented as a percentage. After determining infarct size, tissue samples were taken from non-ischemic and AAR zones and analysed for MPO activity, a presumptive marker of neutrophil accumulation in myocardium, by the method of Mullane et al. [23] . The samples were frozen and stored at -801C. The activity of MPO was measured spectrophotometrically at 460 nm (SPECTRAmax; Molecular Devices, Sunnyvale, California, USA) and expressed as units (U) per 100 g tissue as previous described [24] . Reperfusion injury is reported as the percentage of the 'at-risk' section of the myocardium (the non-blue myocardium) that is necrotic (tan stained with TTC).
Statistical analyses
Analyses were done using Statistica Analysis software (Tulsa, Oklahoma, USA). Data were analysed for normality of distribution and equality of variances among groups. Log transformation was performed for variables that violated the test of equal variances (body weight, plasma lipid levels, uterine weight and mammary gland). Analysis of co-variance (ANCOVA) was used to evaluate the effect of treatment on continuous endpoints (body weight, plasma lipids and lipoproteins) for which there were baseline measures to use as co-variates. Fisher's leastsignificant difference test was used for post-hoc betweengroup comparisons. An a level of 0.05 (two-sided) was used to determine statistical significance. All values reported are mean ± SEM.
Results
Infarct size
The infarct size data are summarized in Figure 2 . The AAR was similar among groups (control = 30 ± 5%; EE and MPA = 27 ± 6%; EE and NETA = 32 ± 6%; P = 0.43). In the control group, infarct size averaged 20.6 ± 2.6%. Infarct size in the monkeys treated with EE and MPA was significantly greater (P = 0.004) than in the control group. In sharp contrast, treatment with EE and NETA was associated with a significantly smaller infarct size than in the EE and MPA group (P = 0.001) and the control group (P = 0.001). The control and CEE and MPA-treated groups had significantly greater (20.6 ± 2.6%, P = 0.02 and 29.1 ± 2.5%, P = 0.01, respectively) infarct size than the EE and NETA-treated group (3.2 ± 2.1%). The AAR was similar among groups (control = 0 ± 5%; EE and MPA = 27 ± 6%; EE and NETA = 32 ± 6%; analysis of variance (ANOVA) = 0.43).
Myeloperoxidase activity
The MPO data are summarized in Figure 3 . MPO values were low and comparable among all three groups in the non-ischemic zone. There was a significant increase in MPO in the AAR tissue compared to the non-ischemic zone tissue. Although there was a modest trend toward lower MPO activity in the AAR tissue in the EE and NETA group, there were no statistically significant differences among the three groups (ANOVA, P = > 0.05).
Blood flow
Regional myocardial blood flow results are summarized in Figure 4 . Myocardial blood flow in non-ischemic left ventricular myocardium was not different among groups (P > 0.05) and was not reduced during coronary artery occlusion (P > 0.05). In contrast, myocardial blood flow in the AAR was reduced in all groups during occlusion (P < 0.05 compared with baseline flow). However, the reduction in AAR blood flow was not significantly different among groups (P > 0.05).
Hemodynamic measurements
Arterial pressure, heart rate, cardiac output, ejection fraction, stroke volume and peripheral vascular resistance were not different among groups at baseline, during coronary occlusion or 4 h after reperfusion (P > 0.05) ( Table 2) .
Body weight and plasma lipids and lipoproteins
There were no significant differences in the mean body weights among the groups at baseline or at necropsy (P > 0.05). The mean body weights (of transformed data) at necropsy time were 3.14 ± 0.16 kg for the control group, 3.02 ± 0.15 kg for the EE and MPA group and 2.95 ± 0.09 kg for the EE and NETA group (ANCOVA, P = 0.26).
The plasma lipid and lipoprotein concentration data are summarized in Table 3 . These values were measured at baseline and after 6 months of treatment. TPC concentrations were significantly increased within each group from baseline values (P < 0.05) after 6 months of atherogenic diet, but there were no significantly different TPC concentrations among the groups at baseline or after treatment (P > 0.05). Much of this increase was caused by similar effects of diet and treatment on plasma LDL-C concentrations. Similarly, plasma triglyceride concentrations were increased from baseline (P < 0.05), but to a greater extent in both treatment groups compared with the control group (P = 0.001 for EE and MPA and 0.03 for EE and NETA). There were no differences in baseline HDL-C concentrations among groups (P > 0.05) and no significant change in HDL-C values at mid-study (P > 0.05).
Discussion
The major finding of this study is that progestins have differential effects on myocardial infarct size following coronary artery occlusion-reperfusion in ovariectomized monkeys receiving estrogen therapy. The hormone combination of EE and MPA was associated with a larger infarct size than for the untreated control group. However, concomitant treatment with NETA reduced infarct size compared with co-treatment with MPA or with the untreated control group. However, the mechanisms underlying these differential effects of progestin on I/R injury remain unclear.
Estrogen and myocardial ischemia-reperfusion injury: modulation by progestogens
There is growing evidence that estrogens reduce myocardial I/R injury. Squandrito et al. [16] reported that 17b-estradiol (E2) reduces cardiac leukocyte accumulation in M/I injury in rats. Stupka and Tiidus reported that estrogen treatment reduced the extent of I/R injury in the hind limbs of female rats [25] . Song et al. [15] reported that ischemic preconditioning with estrogen reduced I/R in mice. Importantly, Shlipak et al. [13] reported that hormone therapy increased in-hospital survival after a myocardial infarction in post-menopausal women, suggesting that hormone therapy may reduce post-infarction myocardial damage.
It has been reported that MPA reduces the beneficial effects of CEE on both progression of atherosclerosis and vascular reactivity [3, 4, 6] . However, other progestins (such as progesterone, norethindrone acetate and nomogestrol acetate) do not appear to reduce the beneficial effects of estrogens on these endpoints [5, 6] . There are no published studies comparing the effects of progestins on I/R injury in post-menopausal subjects receiving estrogens. Results of the current study indicate that there are differences and that the combination of EE and MPA is associated with larger infarct sizes compared to EE hormone replacement therapy containing NETA. Interestingly, the combination of EE and NETA reduced infarct size significantly relative to the control group. Unfortunately, there was no 'estrogen only' treatment group; thus one cannot make inference on estrogen effects independent of the progestins tested. However, the data cited above indicate that estrogen lessens I/R damage. Therefore, it is speculated that MPA, but not NETA, diminished the beneficial effects of EE on I/R injury. The potential explanation for these effects is discussed in the subsequent paragraphs.
Neovascularization
It has been reported that estrogen increases collateral blood formation in the rabbit hind leg [23] and that EE plus NETA increases plasma markers of neovascularization (vascular endothelial growth factor) compared to untreated post-menopausal women [24] . Furthermore, MPA has been shown to inhibit the effects of estrogen on expression of basic fibroblast growth factor (another neovascular marker) [28] and that NETA < MPA in promoting uterine angiogenesis [29, 30] . Therefore, it is possible that infarct size could have been influenced by treatment effects on neovascularization (collateral blood flow) with greater neovascularization causing less relative ischemia during coronary occlusion. However, results of the regional blood blow measurements and the size of AAR (no differences among groups) indicate that there were no significant differences in myocardial collateral blood flow at baseline or during coronary occlusion or 4 h after reperfusion based on treatment type. However, there was an observed trend towards less reduction of myocardial blood flow during coronary occlusion in the EE and NETA group compared to the other two groups (P > 0.05).
Hemodynamics
Coronary artery occlusion resulted in expected reductions in stroke volume, ejection fractions and cardiac output among all groups, thus documenting successful coronary occlusion effects on the myocardium. Similarly, there was post-occlusion suppression of these variables and increases in heart rate documenting that myocardial damage (reduced function) had occurred in all groups. It has been reported that estrogens affect resistance to flow and other hemodynamic variables in monkeys [18] . However, the differential effects of progestins on hemodynamics are less well known. Treatment effects on these hemodynamic and myocardial measures of I/R injury may have altered the amount of blood reaching the myocardium, thus affecting I/R injury size. However, there were no significant effects of treatment on these variables (ANOVA, P > 0.05 for all variables compared with the control group). There was a trend towards more post-ischemia recovery of normal peripheral vascular resistance and cardiac output measures in the EE and NETA group compared with the other groups. However, the results were not statistically significant and hemodynamic or myocardial function variables seem an unlikely cause of treatment effects on I/R injury in this study.
Leukocyte-endothelial cell interactions
The literature varies as to whether estrogens or progestins affect leukocyte-endothelial cell interactions. As mentioned, Squandrito et al. [16] report that E2 reduces leukocyte-endothelial cell interactions after I/R in rats. Studies by Prorock et al. [31] indicate that this protection is related to the effects of E2 on hydroxyl radical formation and nitric oxide and may involve estrogen receptors. Hermenegildo et al. [17] report that E2 is most effective in reducing serum concentrations of MPO in post-menopausal women, then E2 and progesterone and then E2 and MPA [14] . However, Klebanoff [32] reported that E2, but not progesterone or testosterone, inhibits the rise in MPO in response to oxidative stress. Results of the current study do not support a significant effect of treatment on neutrophil accumulation indexed by MPO activity in the AAR myocardium. However, there was a modest trend towards reduced MPO activity in the EE and NETA group compared to the other two groups. It remains unclear if a greater number of observations would have elicited a significant effect.
Lipids and lipoproteins
It has been reported that progestins diminish the beneficial effects of estrogens on lipids and lipoproteins [3, 4] . Diet and treatment produced changes in plasma lipid and lipoprotein concentrations consistent with the results of previous studies using non-human primates [4] [5] [6] and post-menopausal women [1, 2] except for the HDL-C-raising effects seen in women. Because there were no differences among groups in treatment effects on HDL-C, it is unlikely that this difference between monkeys and women explained the differential effects of progestins on myocardial I/R injury. Furthermore, the study group size was not sufficient to make definitive statements about treatment effects on plasma cholesterol concentrations.
Limitations of the studies
As mentioned in the previous paragraphs, the number of observations for the MPO and the blood flow determinations was small compared to those used to determine infarction size. This was due to inadequate tissue sample weights for these analyses because of relatively small infarction sizes (not enough tissue to go around). Based on the data cited, it is possible that one or both of these variables may have explained the treatment effects on I/R injury. Unfortunately, the small number of observations precluded definitive conclusions about treatment effects on MPO as a determinant of I/R in this study. The reduction in myocardial blood flow within the AAR was significant, but not marked. The sample was taken consistently from the center of the AAR, so it is probably not a sampling error. The most likely cause is that monkey myocardium may have considerable collateral flow. There was no 'estrogen only' group. We assumed that the estrogen component of the treatment would have had similar effects on I/R injury, thus the effects observed were due to the progestin component of the therapy. This seems likely, but no definitive statements about 'estrogen effects' can be made. We used an ovariectomy model of menopause and the amount of atherosclerosis was not great. We have found this model to be very useful in predicting the effects of hormones on the vasculature of post-menopausal women [31] but the atherosclerosis was in the beginning plaque stage, which is much less advanced than women having a coronary event. Therefore, the results are not directly applicable to post-menopausal women of the age and with the degree of coronary artery disease that would have a myocardial infarction.
Conclusions and significance
Nothing has stirred a greater controversy than whether estrogen therapy or estrogen and progestin therapy have any cardiovascular benefit in post-menopausal women.
There are now several lines of direct evidence which, despite the conventional thoughts of the early 1990s, suggest that neither CEE nor CEE and MPA therapy reduces the risk of a first or second coronary event in women aged 65 years on average with pre-existing advanced coronary artery disease [1, 2] . However, very little is known about the cardiovascular effects of other estrogen and progestin regimens and even less is known about the effects of estrogen or estrogen and progestin therapy on the amount of myocardial damage that occurs should a post-menopausal women have an infarction. Results of this study indicate that the progestin component of post-menopausal hormone therapy may be critical to the effects of estrogen therapy on postischemic myocardial damage. This report is not intended to promote one product above another. It simply demonstrates that different hormone therapy regimens may produce different effects on different cardiovascular endpoints.
Many post-menopausal women still consider and ask for post-menopausal hormone therapy. Therefore, much more work needs to be done to better define the cardiovascular effects of different hormone therapies.
